[1]孙来顺.氨磺必利与利培酮对精神分裂症患者内分泌及糖脂代谢的影响[J].医学信息,2022,35(10):137-139.[doi:10.3969/j.issn.1006-1959.2022.10.033]
 SUN Lai-shun.Effects of Amisulpride and Risperidone on Endocrine And Glucose and Lipid Metabolism in Patients with Schizophrenia[J].Medical Information,2022,35(10):137-139.[doi:10.3969/j.issn.1006-1959.2022.10.033]
点击复制

氨磺必利与利培酮对精神分裂症患者内分泌及糖脂代谢的影响()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年10期
页码:
137-139
栏目:
论著
出版日期:
2022-05-15

文章信息/Info

Title:
Effects of Amisulpride and Risperidone on Endocrine And Glucose and Lipid Metabolism in Patients with Schizophrenia
文章编号:
1006-1959(2022)10-0137-03
作者:
孙来顺
(天津市宝坻区安康医院精神科,天津 301800)
Author(s):
SUN Lai-shun
(Department of Psychiatry,Baodi District Ankang Hospital,Tianjin 301800,China)
关键词:
精神分裂症氨磺必利利培酮糖脂代谢
Keywords:
SchizophreniaAmisulprideRisperidoneGlucose and lipid metabolism
分类号:
R749.3
DOI:
10.3969/j.issn.1006-1959.2022.10.033
文献标志码:
A
摘要:
目的 探讨氨磺必利与利培酮对精神分裂症患者内分泌及糖脂代谢的影响。方法 选取2019年6月-2021年6月我院收治的68例精神分裂症患者,按照随机数字表法分为氨磺必利组与利培酮组,各34例。氨磺必利组给予氨磺必利治疗,利培酮组给予利培酮治疗,比较两组内分泌指标[血清催乳素(PRL)、三碘甲状腺原氨酸(T3)、甲状腺素(T4)、促甲状腺素(TSH)]、代谢指标[腰围、空腹血糖(FPG)、餐后2h血糖(2hPG)、甘油三酯(TG)、低密度脂蛋白(LDL)、高密度脂蛋白(HDL)]、代谢综合征(MS)发生率及代谢异常率。结果 利培酮组PRL水平高于氨磺必利组(P<0.05);氨磺必利组治疗前后T3、T4、TSH水平比较,差异无统计学意义(P>0.05),而利培酮组治疗后T3、T4、TSH水平低于治疗前,且低于氨磺必利组(P<0.05);利培酮组腰围、FPG、2hPG、TG、LDL水平高于氨磺必利组,HDL水平低于氨磺必利组(P<0.05);利培酮组MS发生率及代谢指标异常率均高于氨磺必利组(P<0.05)。结论 氨磺必利对精神分裂症患者内分泌及糖脂代谢的影响小于利培酮,其代谢异常率相对较低,应用安全性较高。
Abstract:
Objective To investigate the effects of amisulpride and risperidone on endocrine and glucose and lipid metabolism in patients with schizophrenia.Methods A total of 68 patients with schizophrenia admitted to our hospital from June 2019 to June 2021 were randomly divided into amisulpride group and risperidone group, with 34 cases in each group. The amisulpride group was treated with amisulpride, and the risperidone group was treated with risperidone. The endocrine indexes [serum prolactin (PRL), triiodothyronine (T3), thyroxine (T4), thyroid stimulating hormone (TSH)], metabolic indexes [waist circumference, fasting plasma glucose (FPG), 2h postprandial blood glucose (2hPG), triglyceride (TG), low density lipoprotein (LDL), high density lipoprotein (HDL)], metabolic syndrome (MS) incidence and metabolic abnormalities rate were compared between the two groups.Results The level of PRL in risperidone group was higher than that in amisulpride group (P<0.05); there was no significant difference in the levels of T3, T4 and TSH before and after treatment in the amisulpride group (P>0.05),while the levels of T3, T4 and TSH in risperidone group after treatment were lower than those before treatment, and lower than those in amisulpride group (P<0.05). The waist circumference, FPG, 2hPG, TG and LDL levels of risperidone group were higher than those of amisulpride group, and the HDL level was lower than that of amisulpride group (P<0.05). The incidence of MS and abnormal metabolic indexes in risperidone group were higher than those in amisulpride group (P<0.05).Conclusion The effect of amisulpride on endocrine and glycolipid metabolism in patients with schizophrenia is less than risperidone, and its metabolic abnormality rate is relatively low, and its application safety is high.

参考文献/References:

[1]宗爽.利培酮和氨磺必利治疗女性精神分裂症患者的疗效比较[J].中国处方药,2021,19(5):102-104.[2]薛庆玺.氨磺必利与利培酮治疗精神分裂症效果及不良反应的对比观察[J].临床医学,2021,41(3):92-93.[3]廖国栋,蒙雪芳,蓝超越,等.氨磺必利和利培酮治疗女性精神分裂症的效果及对患者糖脂代谢指标的影响[J].中国医药科学,2020,10(1):81-84.[4]李银辉.氨磺必利治疗精神分裂症对患者催乳素及糖脂代谢产生的影响研究[J].中外医学研究,2020,18(18):6-8.[5]徐勇,蒋志锋,何泽民,等.氨磺必利或利培酮治疗首发精神分裂症患者的效果观察及对体质量、糖脂代谢、内分泌的影响[J].临床误诊误治,2020,33(1):25-30.[6]中华医学会精神病学分会.中国精神障碍分类与诊断标准第三版(精神障碍分类)[J].中华精神科杂志,2001,34(3):184-188.[7]Lieberman JA.Disease modifying effects of antipsychotic drugs in schizophrenia: a clinical and neurobiological perspective[J].World Psychiatry,2018,17(2):163-165.[8]程君,夏守翠,汪超,等.氨磺必利与利培酮对女性首发精神分裂症患者生化指标的影响[J]. 临床心身疾病杂志,2017,23(4):28-30.[9]韩笑,崔利军,魏志刚,等.六种非典型抗精神病药物治疗精神分裂症对患者内分泌的影响[J].中国老年学杂志,2019,39(23):5752-5754.[10]付丹,孙东鹏.首发精神分裂症应用氨磺必利与利培酮的疗效[J].包头医学院学报,2016,32(8):43-44.[11]张静,张广亚,袁颖,等.氨磺必利与利培酮对急性期精神分裂症的疗效及血清非酶抗氧化物的影响[J].中国慢性病预防与控制,2021,29(12):939-942.[12]周云山,张莉,张其.氨磺必利对精神分裂症患者血清泌乳素水平及阳性与阴性症状量表分值的影响[J].世界临床药物,2021,42(6):490-494.[13]黄尚岗,阮晓晶,龚俊,等.氨磺必利和利培酮对精神分裂症患者泌乳素及孕酮的影响比较[J].中国药业,2018,27(8):80-82.[14]Howes OD,McCutcheon R.Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization[J].Transl Psychiatry,2017,7(2):e1024.[15]郑鸿伟,王灵君,刘光伟,等.氨磺必利对精分患者的治疗效果及对PRL、糖代谢水平的影响[J].湖南师范大学学报(医学版),2020,17(2):163-166.[16]韩兴玲,王惠玲.氨磺必利与利培酮治疗女性精神分裂症的疗效及不良反应[J].西南国防医药,2018,28(6):531-533.

相似文献/References:

[1]邹超杰,程宇琪.肠道微生物在精神分裂症中的研究进展[J].医学信息,2018,31(02):29.[doi:10.3969/j.issn.1006-1959.2018.02.011]
 ZOU Chao-jie,CHENG Yu-qi.Progress in the Study of Intestinal Microorganism in Schizophrenia[J].Medical Information,2018,31(10):29.[doi:10.3969/j.issn.1006-1959.2018.02.011]
[2]张 健,江 芮.生活技能训练对精神分裂症缓解期患者日常生活能力的影响[J].医学信息,2018,31(03):118.[doi:10.3969/j.issn.1006-1959.2018.03.040]
 ZHANG Jian,JIANG Rui.Effect of Life Skills Training on Daily Living Ability of Patients with Schizophrenia in Remission Staged[J].Medical Information,2018,31(10):118.[doi:10.3969/j.issn.1006-1959.2018.03.040]
[3]沈雪梅.齐拉西酮与奥氮平治疗首发精神分裂症 疗效及糖脂代谢的影响观察[J].医学信息,2018,31(06):130.[doi:10.3969/j.issn.1006-1959.2018.06.044]
 SHEN XUE-mei.The Effect of Ziprasidone and Olanzapine in the Treatment of First Episode Schizophrenia and the Effect of Glycolipid Metabolism[J].Medical Information,2018,31(10):130.[doi:10.3969/j.issn.1006-1959.2018.06.044]
[4]陈功琦,梁道博.利培酮联合舍曲林治疗精神分裂症阴性症状 疗效和安全性的Meta分析[J].医学信息,2018,31(10):65.[doi:10.3969/j.issn.1006-1959.2018.10.020]
 CHEN Gong-qi,LIANG Dao-bo.Meta Analysis of Efficacy and Safety of Risperidone Combined with Sertraline in the Treatment of Schizophrenia with Negative Symptoms[J].Medical Information,2018,31(10):65.[doi:10.3969/j.issn.1006-1959.2018.10.020]
[5]孙占娟.精神分裂症患者的认知康复治疗进展[J].医学信息,2018,31(13):52.[doi:10.3969/j.issn.1006-1959.2018.13.015]
 SUN Zhan-juan.Progress in Cognitive Rehabilitation Therapy of Schizophrenia Patients[J].Medical Information,2018,31(10):52.[doi:10.3969/j.issn.1006-1959.2018.13.015]
[6]吴金丽.阿立哌唑的临床应用[J].医学信息,2018,31(14):42.[doi:10.3969/j.issn.1006-1959.2018.14.014]
 WU Jin-li.Clinical Application of Aripiprazole[J].Medical Information,2018,31(10):42.[doi:10.3969/j.issn.1006-1959.2018.14.014]
[7]宋典雄.激励理论指导下的护理干预对精神分裂症患者的影响[J].医学信息,2018,31(18):166.[doi:10.3969/j.issn.1006-1959.2018.18.054]
 SONG Dian-xiong.The Effect of Nursing Intervention under the Guidance of Motivation Theory on Patients with Schizophrenia[J].Medical Information,2018,31(10):166.[doi:10.3969/j.issn.1006-1959.2018.18.054]
[8]凌 梅,刘静芳.精神分裂症患者研究伙伴的相关研究进展[J].医学信息,2018,31(19):48.[doi:10.3969/j.issn.1006-1959.2018.19.016]
 LING Mei,LIU Jing-fang.Progress in Research on Research Partners in Patients with Schizophrenia[J].Medical Information,2018,31(10):48.[doi:10.3969/j.issn.1006-1959.2018.19.016]
[9]韩佳睿,张 苹,张 媛.迟发性运动障碍与DNA甲基化之间关系的研究进展[J].医学信息,2018,31(20):32.[doi:10.3969/j.issn.1006-1959.2018.20.010]
 HAN Jia-rui,ZHANG Ping,ZHANG Yuan.Advances in Research on the Relationship between Tardive Dyskinesia and DNA Methylation[J].Medical Information,2018,31(10):32.[doi:10.3969/j.issn.1006-1959.2018.20.010]
[10]陈宽玉,孔 骞,黄玉桃.首发缓解期精神分裂症患者日常生活模式的调查[J].医学信息,2019,32(04):182.[doi:10.3969/j.issn.1006-1959.2019.04.061]
 CHEN Kuan-yu,KONG Qian,HUANG Yu-tao.Investigation on the Daily Life Pattern of Patients with Schizophrenia in the First Remission Period[J].Medical Information,2019,32(10):182.[doi:10.3969/j.issn.1006-1959.2019.04.061]
[11]孙来顺.氨磺必利治疗阴性症状为主的精神分裂症患者的疗效[J].医学信息,2021,34(22):136.[doi:10.3969/j.issn.1006-1959.2021.22.042]
 SUN Lai-shun.Efficacy of Amisulpride in the Treatment of Schizophrenia Patients with Negative Symptoms[J].Medical Information,2021,34(10):136.[doi:10.3969/j.issn.1006-1959.2021.22.042]
[12]孙来顺.氨磺必利与利培酮治疗精神分裂症阴性症状的疗效比较[J].医学信息,2022,35(07):121.[doi:10.3969/j.issn.1006-1959.2022.07.030]
 SUN Lai-shun.Comparison of Therapeutic Effects of Amisulpride and Risperidone on Negative Symptoms of Schizophrenia[J].Medical Information,2022,35(10):121.[doi:10.3969/j.issn.1006-1959.2022.07.030]

更新日期/Last Update: 1900-01-01